How device makers buy, and what would change that
The recommendation depends on other companies deciding to buy rather than make, which has to be derived from what they compete on rather than from what they do today.
The recommendation depends on other companies deciding to buy from MERIDIAN rather than make it themselves. That has to be derived from what they compete on, not from what they happen to do today.
The rule: a device maker keeps in-house whatever it competes on, and buys whatever it does not. Price alone does not move a component that sits close to what the company competes on, because the risk of a supply failure or a quality event on that part is larger than the saving. Something the company cannot do itself will move it, at almost any price.
Applying the rule, in ascending order of how strong the proposition is:
Being cheaper than what they do today is the weakest case. It moves nobody on a part they consider core.
Removing a capacity constraint is stronger. Abbott opened a new facility specifically to meet CGM demand, which says capacity is binding on the part it competes on.
Removing a capability they do not have is strongest. A pharmaceutical company launching an on-body injector has no electronics plant and no intention of building one.
Segment by segment:
CGM sensors are the entire product. Abbott, Dexcom and Medtronic all manufacture their own, and the Chinese entrants are vertically integrated by design, because undercutting Abbott by 30% to 40% is their whole proposition. Nothing MERIDIAN offers changes that, because a cheaper sensor electrode does not remove a constraint any of them has. Merchant share is confined to new entrants and second-source qualification. This analysis puts it at 5%.
Neurostimulation leads and electrodes are already outsourced in part, which is Cirtec's and Integer's stated business, so the rule is confirmed by existing behavior. The four majors retain substantial in-house capacity. Merchant share around 30%.
On-body injectors, patch pumps and diagnostic cartridges are made for companies that are not device manufacturers at all. Merchant share around 70%, and the proposition is the strongest of the three kinds.
Private-label electrodes are already a contract business, but a contract business competing purely on cost.
The rule also predicts an actor not yet observed. A new CGM entrant carrying none of Abbott's sunk sensor-plant investment applies the same rule and reaches a different answer: it has no in-house capacity to protect, so it buys. That is the one route into CGM worth pursuing, and it is a route to challengers rather than to incumbents.
MERIDIAN's own business is an instance of the same decision, and it is evidence. Smartphone makers buy CoF substrates from MERIDIAN rather than making them, because a display interconnect is not what a phone competes on. They also squeeze the price every year, which is why the margin is low. That is exactly what MERIDIAN should expect from a device OEM buying a printed electrode.
Are the existing NDAs and discussions durable demand
The brief asks this directly and treats it as blocking, so it deserves a ruling rather than a deferral.
The evidence available is what the brief states: NDAs with multiple global top-tier CGM and BCI companies, PoC discussions with several, two to three commercial contracting discussions in process, a CGM substrate and module development with a major CGM company, a neurostimulation electrode discussion, and five years of neurostimulation development through a startup.
The ruling: this is real technical interest and it is not yet evidence of durable demand, and the reason is structural rather than a doubt about MERIDIAN's counterparties.
An NDA costs a device company nothing and commits it to nothing. Large device makers run many parallel supplier evaluations because dual-sourcing and technology scouting are standing obligations of their quality systems, not signals of intent. The rule stated above predicts this: with the CGM makers, the sensor is what they compete on, so an evaluation is exactly what one would expect and a purchase order is not. The two to three contracting discussions are the only items in the list that could become revenue, and the brief does not say what they are for, at what volume, or with whom.
What would convert these into evidence, in ascending order of strength: a paid development agreement, a specification frozen against a named customer program, a qualification audit scheduled, and a volume commitment. None of the first three requires the ISO 13485 certificate to exist, which means MERIDIAN can gather this evidence in 2027 while recertification runs, and it is why the test program is built around a development agreement rather than around interest.
The one thing that would change this ruling immediately is if any of the two or three contracting discussions is with a CGM challenger rather than an incumbent. A challenger with no sensor plant is buying because it has to, and that is durable in a way an incumbent's evaluation is not.
Section added · The recommendation turns on another party's decision to source externally. That has to be derived from what those buyers compete on, not reported from their current behavior.